GenPath® ONCOLOGY

Final Report

PHYSICIAN	PATIENT	SAMPLE
DESAI, SAMEER ASTERA CANCER CARE - ROBBINSVILLE 1 Washington Blvd, Suite 9 Robbinsville, NJ 08691 Acct#: **(JN036-2) NJ114** Tel: (732) 390-7750	**MALAGRINO, JAMES** **DOB:** 06/09/1942 **Age:** 83 Y **Sex:** F **ID:** 443449 **Address:** 316 SILVER CT TRENTON, NJ 08690	**Specimen ID:** **102470598** **Date Of Report:** 08/15/2025 **Time Of Report:** 03:59 **Date Collected:** 08/14/2025 **Time Collected:** 15:08 **Date Received:** 08/15/2025 **Time Received:** 00:24 North America Eastern Time

CLINICAL REPORT

CLINICAL ABNORMALITIES SUMMARY:

(May not contain all abnormal results: narrative results may not have abnormal flags. Please review entire report.)

EOS 5.4 H

Initial Receipt Date: 08/15/2025

NON FASTING

CHEMISTRY

Test	Result	Abnormal	Reference	Units	Rpt Date	Prior Result	Date
Total Protein	6.7		5.9-8.4	g/dL	08/15/25	7.0	07/18/25
Albumin	4.4		3.5-5.2	g/dL	08/15/25	4.2	07/18/25
Globulin	2.3		1.7-3.7	g/dL	08/15/25	2.8	07/18/25
A/G Ratio	1.9		1.1-2.9	Ratio	08/15/25	1.5	07/18/25
Glucose	85		70-99	mg/dL	08/15/25	86	07/18/25
Sodium	139		135-147	mmol/L	08/15/25	141	07/18/25
Potassium	4.3		3.5-5.5	mmol/L	08/15/25	4.4	07/18/25
Chloride	102		96-108	mmol/L	08/15/25	104	07/18/25
CO2	21		19-29	mmol/L	08/15/25	24	07/18/25
BUN	12		8-23	mg/dL	08/15/25	10	07/18/25
Creatinine	0.85		0.49-1.02	mg/dL	08/15/25	0.92	07/18/25
e-GFR	68		>or=60	mL/min	08/15/25	62	07/18/25

GFR categories in CKD

Category	GFR ml/min/1.73 m2	Terms
G1	>or=90	Normal or high
G2	60-89	Mildly decreased*
G3a	45-59	Mildly to moderately decreased
G3b	30-44	Moderately to severely decreased
G4	15-29	Severely decreased
G5	<15	Kidney failure

Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
*Relative to young adult level.
In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD.

NOTE: The National Kidney Foundation recommends using the CKD-EPI Creatinine Equation (2021) to estimate GFR in adults. The new CKD-EPI equation is in use 3/6/2023.

BUN/Creat Ratio	14.1	10.0-28.0	Ratio	08/15/25	10.9	07/18/25
Calcium	9.4	8.6-10.4	mg/dL	08/15/25	9.1	07/18/25
Bilirubin, Total	0.4	<1.2	mg/dL	08/15/25	0.8	07/18/25
Alk Phos	84	40-156	U/L	08/15/25	81	07/18/25
AST	20	<32	U/L	08/15/25	20	07/18/25
ALT	11	<33	U/L	08/15/25	12	07/18/25

PHYSICIAN	PATIENT	SAMPLE
DESAI, SAMEER ASTERA CANCER CARE - ROBBINSVILLE 1 Washington Blvd, Suite 9 Robbinsville, NJ 08691 Acct#: **(JN036-2) NJ114** Tel: (732) 390-7750	**MALAGRINO, JAMES** **DOB:** 06/09/1942 **Age:** 83 Y **Sex:** F **ID:** 443449 **Address:** 316 SILVER CT TRENTON, NJ 08690	**Specimen ID:** **102470598** **Date Of Report:** 08/15/2025 **Time Of Report:** 03:59 **Date Collected:** 08/14/2025 **Time Collected:** 15:08 **Date Received:** 08/15/2025 **Time Received:** 00:24 North America Eastern Time

CLINICAL REPORT

HEMATOLOGY

Test	Result	Abnormal	Reference	Units	Rpt Date	Prior Result	Date
WBC	5.94		4.00-10.10	x10(3)/uL	08/15/25	5.06	07/18/25
RBC	4.32		3.58-5.19	x10(6)/uL	08/15/25	4.57	07/18/25
HGB	13.2		11.0-15.5	g/dL	08/15/25	13.7	07/18/25
HCT	41.3		31.5-44.8	%	08/15/25	43.7	07/18/25
MCV	95.6		78.0-98.0	fL	08/15/25	95.6	07/18/25
MCH	30.6		25.2-32.6	pg	08/15/25	30.0	07/18/25
MCHC	32.0		31.0-34.7	g/dL	08/15/25	31.4	07/18/25
RDW	12.8		12.0-15.5	%	08/15/25	13.2	07/18/25
POLYS	68.1		37.1-78.1	%	08/15/25	73.2	07/18/25
POLYS, ABS. COUNT	4.05		1.30-7.00	x10(3)/uL	08/15/25	3.71	07/18/25
LYMPHS	15.0		13.7-50.9	%	08/15/25	*12.1 L*	07/18/25
LYMPHS, ABS. COUNT	0.89		0.80-3.00	x10(3)/uL	08/15/25	*0.61 L*	07/18/25
MONOS	10.3		3.0-11.9	%	08/15/25	10.3	07/18/25
MONOS, ABS. COUNT	0.61		0.00-1.00	x10(3)/uL	08/15/25	0.52	07/18/25
EOS		*5.4 H*	0.0-5.0	%	08/15/25	3.4	07/18/25
EOS, ABS. COUNT	0.32		0.00-0.40	x10(3)/uL	08/15/25	0.17	07/18/25
BASOS	0.7		0.0-1.0	%	08/15/25	0.8	07/18/25
BASOS, ABS. COUNT	0.04		0.00-0.10	x10(3)/uL	08/15/25	0.04	07/18/25
IMMATURE GRANULOCYTES	0.5		0.0-1.0	%	08/15/25	0.2	07/18/25
IG, ABS. COUNT	0.03		0.00-0.09	x10(3)/uL	08/15/25	0.01	07/18/25
PLATELET COUNT	218		140-425	x10(3)/uL	08/15/25	238	07/18/25
MPV	9.6		8.6-12.1	fL	08/15/25	9.0	07/18/25
PT	10.6		10.0-12.5	sec	08/15/25	10.8	07/18/25
INR	1.0		0.9-1.1		08/15/25	1.0	07/18/25

Suggested INR therapeutic ranges for patients on warfarin:

Moderate intensity therapeutic range: 2.0-3.0
(Prophylaxis and Thrombosis)

High intensity therapeutic range: 2.5-3.5
(Mechanical Prosthetic Valves)

PTT	29.6		23.3-36.2	sec	08/15/25	28.9	07/18/25

NOTE: The modified activated Partial Thromboplastin Time (APTT) is a screening procedure for assessment of secondary coagulation, e.g. whether sufficient fibrinogen and plasma factors are present in amounts for adequate hemostasis. The extension of the stability to 24 hours for the APTT is only valid in its use as an initial screening assay of non-hospitalized patient population. Assessment of factor assays, unfractionated heparin monitoring, mixing studies, and evaluation for antiphospholipid-associated APTT abnormalities ("Lupus anticoagulant") requires strict frozen plasma.

PHYSICIAN	PATIENT	SAMPLE
DESAI, SAMEER ASTERA CANCER CARE - ROBBINSVILLE 1 Washington Blvd, Suite 9 Robbinsville, NJ 08691 Acct#: **(JN036-2) NJ114** Tel: (732) 390-7750	**MALAGRINO, JAMES** **DOB:** 06/09/1942 **Age:** 83 Y **Sex:** F **ID:** 443449 **Address:** 316 SILVER CT TRENTON, NJ 08690	**Specimen ID:** **102470598** **Date Of Report:** 08/15/2025 **Time Of Report:** 03:59 **Date Collected:** 08/14/2025 **Time Collected:** 15:08 **Date Received:** 08/15/2025 **Time Received:** 00:24 North America Eastern Time

CLINICAL REPORT

MISCELLANEOUS

Test	Result	Abnormal	Reference	Units	Rpt Date	Prior Result	Date
CEA	1.9		See Below	ng/mL	08/15/25	2.0	07/18/25

CEA INTERPRETATION

	Range (ng/mL)
Non-Smoker	< or=3.8
Smokers	< or=5.5

NOTE: The CEA assay should not be used as a cancer screening test.
CEA results should not be interpreted as absolute evidence for the presence or absence of malignant disease.
NOTE: Values obtained with different assay methods or kits cannot be used interchangeably.

ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics).

Final Report